Effects of the active parts of Yangxin Tongmai Formula on myocardial injury and spatial metabolic remodeling in rats with myocardial ischemia-reperfusion injury

• by Di Ye, Yi Wang, Ziyuan Zhao, Caiyue Lin, Wenhua Xu, Jinghui Zheng

• July 20, 2026

Magnetocardiography in the diagnosis of suspected ANOCA: a case series

• by Xiaoyan Xue, Jiandong Zhang, Yuheng Zhou, Lei Cheng, Yihao Zhu, Jiaqi Liang, Kangqi Tian, Dong Xu, Shuting Xiang, Qian Li, Jun Xiao, Yu Ma, Xu Zhang, Min Xiang

• June 19, 2026

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

• by Kathryn Wighton

• July 16, 2026

• 2 min

Biomolecular mechanisms of cardiac amyloidosis and its cardiovascular pathological basis

• by Linlin Zhang, YaTing Jiao, Jia Guo

• May 29, 2026